Storys aus Japan

27.05.2014 – 14:17
Takeda Pharmaceutical Company Limited
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease
Zurich And Osaka, Japan (ots/PRNewswire) - Discovery Minerals (DSCR) Undervalued and Nearing Its SqueezeTrigger Price According to WealthMakers.com Report May 27, 2014 WEALTHMAKERS.COM / www.wealthmakers.com [http://www.wealthmakers.com ] , a Wall Street research and trading firm providing unbiased statistical stock ...
mehr
28.03.2014 – 13:07
Dainippon Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Company Limited
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the European Commission has granted Marketing Authorization for once-daily oral Latuda(R) (lurasidone) ...
mehr
24.01.2014 – 16:10
Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has ...
mehr
24.09.2013 – 08:01
Takeda Pharmaceutical Company Limited
Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ? (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ? (alogliptin and metformin) and Incresync[TM] ? (alogliptin and pioglitazone)
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on ...
mehr
25.10.2012 – 08:04
Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization ...
mehr
04.09.2012 – 13:02
Takeda Pharmaceutical Company Limited
Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) ...
mehr
22.06.2012 – 14:21
Takeda Pharmaceutical Company Limited
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - European CHMP adopts positive opinion for teduglutide (Revestive(R)) for patients with short bowel syndrome (SBS) - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications - ...
mehr
25.05.2012 – 10:22
Takeda Pharmaceutical Company Limited
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda ...
mehr
27.02.2012 – 09:03
Takeda Pharmaceutical Company Limited
Takeda Announces Acceptance of European Marketing Authorisation Application for Peginesatide, an Investigational Compound for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
London And Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd received confirmation of acceptance for assessment from the European Medicines Agency (EMA) for a Marketing Authorisation Application (MAA) for the ...
mehr
15.02.2012 – 11:39
Renesas Mobile Corporation
Renesas Mobile Introduces First Integrated LTE Triple-Mode Platform Optimised for Full-Featured, High Volume Smartphones
Tokyo, Japan (ots) - MP5232 Dual 1.5GHz core Communications Processor to Drive LTE Growth with Best-in-Class User Experience for High Volume LTE Smartphones and Tablets Renesas Electronics Corporation (TSE: 6723) and its subsidiary, Renesas Mobile Corporation (http://www.renesasmobile.com), a leading supplier of ...
mehr
18.01.2012 – 10:03
Takeda Pharmaceutical Company Limited
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and ...
mehr
08.12.2011 – 16:23
Takeda Pharmaceutical Company Limited
Takeda's Edarbi® (azilsartan medoxomil) Receives European Marketing Authorisation for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted marketing authorisation for Edarbi(R) (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist ...
mehr
30.09.2011 – 13:02
Takeda Pharmaceutical Company Limited
Takeda Completes Acquisition and Names New CEO of Nycomed
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations ...
mehr
23.09.2011 – 14:29
Takeda Pharmaceutical Company Limited
Takeda Receives Positive CHMP Opinion in Europe for Edarbi(TM) (azilsartan medoxomil) for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for EdarbiTM (azilsartan medoxomil, development code: TAK-491), a new ...
mehr

Vorherige12